Keystone Wealth Services LLC Sells 204 Shares of Amgen Inc. (NASDAQ:AMGN)

Keystone Wealth Services LLC lowered its stake in Amgen Inc. (NASDAQ:AMGNFree Report) by 8.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,301 shares of the medical research company’s stock after selling 204 shares during the quarter. Keystone Wealth Services LLC’s holdings in Amgen were worth $654,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Fuller & Thaler Asset Management Inc. lifted its stake in Amgen by 1.7% in the third quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock valued at $3,133,000 after buying an additional 193 shares in the last quarter. Diversified Trust Co raised its holdings in shares of Amgen by 76.8% in the fourth quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock valued at $10,857,000 after purchasing an additional 16,376 shares during the last quarter. Provence Wealth Management Group raised its holdings in shares of Amgen by 11.9% in the fourth quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company’s stock valued at $416,000 after purchasing an additional 154 shares during the last quarter. Kinsale Capital Group Inc. raised its holdings in shares of Amgen by 33.0% in the fourth quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company’s stock valued at $3,269,000 after purchasing an additional 2,814 shares during the last quarter. Finally, Global Wealth Management Investment Advisory Inc. raised its holdings in shares of Amgen by 2.4% in the fourth quarter. Global Wealth Management Investment Advisory Inc. now owns 4,733 shares of the medical research company’s stock valued at $1,363,000 after purchasing an additional 109 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the sale, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.69% of the stock is currently owned by company insiders.

Amgen Stock Performance

Shares of Amgen stock traded up $5.09 during trading on Tuesday, reaching $323.24. The company’s stock had a trading volume of 877,550 shares, compared to its average volume of 2,770,010. The business’s 50-day moving average price is $297.62 and its 200-day moving average price is $291.17. The firm has a market cap of $173.40 billion, a PE ratio of 46.37, a P/E/G ratio of 2.78 and a beta of 0.60. Amgen Inc. has a 52 week low of $218.44 and a 52 week high of $329.72. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96.

Amgen (NASDAQ:AMGNGet Free Report) last announced its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. The company had revenue of $7.45 billion during the quarter, compared to analysts’ expectations of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. Amgen’s quarterly revenue was up 22.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.98 earnings per share. Equities analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AMGN. William Blair upgraded shares of Amgen from a “market perform” rating to an “outperform” rating in a report on Friday, May 3rd. UBS Group lifted their price objective on shares of Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. TD Cowen lowered their price objective on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Morgan Stanley lifted their price objective on shares of Amgen from $271.00 to $310.00 and gave the company an “equal weight” rating in a report on Friday, May 3rd. Finally, Barclays upgraded shares of Amgen from an “underweight” rating to an “equal weight” rating and boosted their target price for the stock from $230.00 to $300.00 in a report on Friday, May 3rd. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $305.85.

View Our Latest Stock Report on AMGN

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

See Also

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.